Search Result

Results for "

SST

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenylate Cyclase (2) Akt (1) CDK (1) Dopamine Receptor (1) EGFR (1) GHSR (1) HSP (1) Small Interfering RNA (siRNA) (1) Somatostatin Receptor (30) Urotensin Receptor (1) γ-secretase (1)
By Research Areas:	Cancer (13) Cardiovascular Disease (5) Endocrinology (12) Inflammation/Immunology (5) Metabolic Disease (2) Neurological Disease (15)
Oligonucleotides:	Pre-designed siRNA Sets (1) siRNAs (1)

Inhibitors & Agonists

Peptides

MCE Kits

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P1206

CH 275	Somatostatin Receptor	Neurological Disease
CH 275 is a peptide analog of somatostatin and binds preferably to somatostatin receptor 1 (sst₁) with a K_i of 52 nM . CH 275 acts as a potent and selective sst₁ agonist (IC₅₀=30.9 nM) and also displays IC₅₀ values of 345 nM, >1 μM, >10 μM, >10 μM for human sst₃, sst₄, sst₂ and sst₅, respectively . CH 275 can be used for the research of alzheimer’s disease .

HY-P1202

CYN 154806 1 Publications Verification	Somatostatin Receptor	Endocrinology
CYN 154806, a cyclic octapeptide, is a potent and selective *somatostatin sst2 receptor* antagonist, with pIC₅₀ values of 8.58, 5.41, 6.07, 5.76 and 6.48 for human recombinant sst2, sst1, sst3, sst4 and sst5 receptors respectively .

HY-P1202A

CYN 154806 TFA 1 Publications Verification	Somatostatin Receptor	Endocrinology
CYN 154806 TFA, a cyclic octapeptide, is a potent and selective somatostatin sst2 receptor antagonist, with pIC₅₀ values of 8.58, 5.41, 6.07, 5.76 and 6.48 for human recombinant sst2, sst1, sst3, sst4 and sst5 receptors respectively .

HY-P1932

Cortistatin-14	Somatostatin Receptor	Neurological Disease Inflammation/Immunology Endocrinology
Cortistatin-14 is a neuropeptide that shares structural similarities with somatostatin, working by binding to somatostatin receptors (sst1-sst5). Cortistatin-14 (TFA) has anticonvulsant, neuroprotective effects, and significant anti-inflammatory properties .

HY-P1932A

Cortistatin-14 TFA	Somatostatin Receptor	Neurological Disease Inflammation/Immunology Endocrinology
Cortistatin-14 (TFA), a neuropeptide have structural similarity to somatostatin-14, binds and exerts its function via the somatostatin receptors (sst1-sst5). Cortistatin-14 (TFA) shows anticonvulsive, neuroprotective effect and remarkable anti-inflammatory properties .

HY-P1203

BIM-23056	Somatostatin Receptor	Neurological Disease
BIM 23056, a linear octapeptide, is a potent *sst3* and *sst5* somatostatin receptor antagonist with K_i values of 10.8, 5.7, respectively .

HY-164399

SST0116CL1	HSP EGFR CDK Akt	Cancer
SST0116CL1 is a HSP90 inhibitor (IC₅₀: 0.21 μM). SST0116CL1 binds to the ATP binding pocket of Hsp90, and interferes with Hsp90 chaperone function thus resulting in client protein (EGFR, CDK4 and AKT) degradation. SST0116CL1 induces degradation of Her2 in BT-474 cell (IC₅₀: 0.2 μM). SST0116CL1 has antiproliferative activity and inhibits tumor growth .

HY-110161

sst2 Receptor agonist-1	Somatostatin Receptor	Cardiovascular Disease Endocrinology
sst2 Receptor agonist-1 is a potent somatostatin receptor subtype 2 (sst₂) agonist with a K_i value of 0.025 nM and a cAMP IC₅₀ value of 4.8 nM. sst2 Receptor agonist-1 can inhibit rat growth hormone (GH) secretion and ocular neovascular lesion formation. Antiangiogenic effect .

HY-RS13819

SST Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
SST Human Pre-designed siRNA Set A contains three designed siRNAs for SST gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

SST Human Pre-designed siRNA Set A SST Human Pre-designed siRNA Set A

HY-P4469

PRL 3195	Somatostatin Receptor Urotensin Receptor	Cardiovascular Disease
PRL 3195 is a somatostatin receptor antagonist with K_is of 6, 17, 66, 1000 and 1000 nM for human somatostatin receptors (sst₅, sst₂, sst₃, sst₁ and sst₄, respectively) .

HY-P1203A

BIM-23056 TFA	Somatostatin Receptor	Neurological Disease
BIM 23056 TFA, a linear octapeptide, is a potent *sst3* and *sst5* somatostatin receptor antagonist with K_i values of 10.8, 5.7, respectively .

HY-P2090

Angiopeptin	Somatostatin Receptor Adenylate Cyclase	Cardiovascular Disease
Angiopeptin, a cyclic octapeptide analogue of somatostatin, is a weak *sst₂/sst₅* receptor partial agonist with IC₅₀ values of 0.26 nM and 6.92 nM, respectively. Angiopeptin is a potent inhibitor of growth hormone release and insulin-like growth factor-1 (IGF-1) production. Angiopeptin inhibits adenylate cyclase or stimulates extracellular acidification. Angiopeptin has the potential for coronary atherosclerosis research .

HY-P2090A

Angiopeptin TFA	Somatostatin Receptor Adenylate Cyclase	Cardiovascular Disease
Angiopeptin TFA, a cyclic octapeptide analogue of somatostatin, is a weak *sst₂/sst₅* receptor partial agonist with IC₅₀ values of 0.26 nM and 6.92 nM, respectively. Angiopeptin TFA is a potent inhibitor of growth hormone release and insulin-like growth factor-1 (IGF-1) production. Angiopeptin TFA inhibits adenylate cyclase or stimulates extracellular acidification. Angiopeptin TFA has the potential for coronary atherosclerosis research .

HY-123499

SRA880	Somatostatin Receptor	Cardiovascular Disease
SRA880 is a non-peptide and selective *somatostatin sst(1) receptor* antagonist. SRA880 exhibits antidepressant-like effects when in combination with Imipramine (HY-B1490A) .

HY-111615

J-2156	Somatostatin Receptor	Neurological Disease
J-2156 is a high potent, selective *somatostatin receptor type 4 (SST4 receptor)* agonist with IC₅₀s of 0.05 nM and 0.07 nM for human and rat SST4 receptors, respectively. J-2156 is used for the relief of mechanical allodynia and mechanical hyperalgesia in the ipsilateral hindpaws in rats .

HY-79135

Pasireotide ditrifluoroacetate 5 Publications Verification SOM230 ditrifluoroacetate; Pasireotide TFA salt	Somatostatin Receptor	Endocrinology Cancer
Pasireotide (SOM230) ditrifluoroacetate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes *sst1/2/3/4/5, pK_i*=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide ditrifluoroacetate exhibits antisecretory, antiproliferative, and proapoptotic activity .

HY-108768

Pasireotide pamoate SOM230 pamoate	Somatostatin Receptor	Endocrinology Cancer
Pasireotide (SOM230) pamoate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes *sst1/2/3/4/5, pK_i*=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide pamoate exhibits antisecretory, antiproliferative, and proapoptotic activity .

HY-16381B

Pasireotide (diaspartate) SOM230 (diaspartate)	Somatostatin Receptor	Neurological Disease Cancer
Pasireotide (SOM230) diaspartate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes *sst1/2/3/4/5, pK_i*=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide diaspartate exhibits antisecretory, antiproliferative, and proapoptotic activity .

HY-79136

Pasireotide L-aspartate salt 5 Publications Verification SOM230 L-aspartate	Somatostatin Receptor	Endocrinology Cancer
Pasireotide (SOM230) L-aspartate salt, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes *sst1/2/3/4/5, pK_i*=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide L-aspartate salt exhibits antisecretory, antiproliferative, and proapoptotic activity .

HY-111615A

J-2156 TFA	Somatostatin Receptor	Neurological Disease Inflammation/Immunology
J-2156 TFA is a high potent, selective *somatostatin receptor type 4 (SST₄* receptor) agonist with IC₅₀*s of 0.05 nM and 0.07 nM for human and rat SST₄* receptors, respectively. J-2156 TFA has anti-inflammatory activity and it is used for the relief of mechanical allodynia and mechanical hyperalgesia in the ipsilateral hindpaws in rats .

HY-108497A

L-803087 TFA	Somatostatin Receptor	Neurological Disease Cancer
L-803087 TFA is a potent and selective *somatostatin sst4 receptor* agonist with a K_i of 0.7 nM. L-803087 TFA is >280-fold more selective for sst4 receptor than other somatostatin receptors. L-803087 TFA facilitates AMPA-mediated hippocampal synaptic responses in vitro and increases kainate-induced seizures in mice .

HY-16381

Pasireotide 5 Publications Verification SOM230	Somatostatin Receptor	Endocrinology Cancer
Pasireotide (SOM230), a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes *sst1/2/3/4/5, pK_i*=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide can suppress GH, IGF-I and ACTH secretion, indicating potential efficacy in acromegaly and Cushing's disease. Pasireotide also exhibits antisecretory, antiproliferative, and proapoptotic activity .

HY-16381A

Pasireotide acetate 5 Publications Verification SOM230 acetate	Somatostatin Receptor	Endocrinology Cancer
Pasireotide (SOM230) acetate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes *sst1/2/3/4/5, pK_i*=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide acetate can suppress GH, IGF-I and ACTH secretion, indicating potential efficacy in acromegaly and Cushing's disease. Pasireotide acetate also exhibits antisecretory, antiproliferative, and proapoptotic activity .

HY-164040

Zavolosotine	Somatostatin Receptor	Metabolic Disease
Zavolosotine (Compound 1) is an orally active agonist for somatostatin receptor type 5 (SST5) with EC₅₀ <1 nM. Zavolosotine inhibits insulin and glucagon secretion, increases levels of glucagon in blood in rat model .

HY-P3294

Onzigolide BIM-23A760; TBR-760	Dopamine Receptor Somatostatin Receptor	Neurological Disease Cancer
Onzigolide (BIM-23A760), a chimeric dopamine-somatostatin compound, shows potent agonist activity at both DA type 2 (D2R) and SST type 2 (SSTR2) receptors .

HY-P1201

Cyclosomatostatin	Somatostatin Receptor	Cancer
Cyclosomatostatin is a potent somatostatin (SST) receptor antagonist. Cyclosomatostatin can inhibit somatostatin receptor type 1 (SSTR1) signaling and decreases cell proliferation, ALDH+ cell population size and sphere-formation in colorectal cancer (CRC) cells .

HY-108499

NNC 26-9100	Somatostatin Receptor γ-secretase	Neurological Disease
NNC 26-9100 is a selective somatostatin *sst4* receptor full agonist (K_i: 6 nM, EC₅₀: 2 nM). NNC 26-9100 decreases total soluble Aβ42, increases brain neprilysin activity and improves learning .

HY-P1201A

Cyclosomatostatin TFA	Somatostatin Receptor	Cancer
Cyclosomatostatin TFA is a potent somatostatin (SST) receptor antagonist. Cyclosomatostatin TFA can inhibit somatostatin receptor type 1 (SSTR1) signaling and decreases cell proliferation, ALDH+ cell population size and sphere-formation in colorectal cancer (CRC) cells .

HY-109155

Paltusotine 1 Publications Verification CRN00808	Somatostatin Receptor	Endocrinology Cancer
Paltusotine (CRN00808) is an orally active, nonpeptide selective *somatostatin type 2 (SST2) receptor* agonist. Paltusotine has the potential for maintaining GH and IGF-1 levels after depot somatostatin receptor ligand therapy.Paltusotine can be used in research on acromegaly and neuroendocrine tumors .

HY-109155A

Paltusotine hydrochloride CRN00808 hydrochloride	Somatostatin Receptor	Neurological Disease Endocrinology
Paltusotine (CRN00808) hydrochloride is an orally active, nonpeptide selective *somatostatin type 2 (SST2) receptor* agonist. Paltusotine hydrochloride has the potential for maintaining GH and IGF-1 levels after depot somatostatin receptor ligand therapy.Paltusotine hydrochloride can be used in research on acromegaly and neuroendocrine tumors .

HY-108497

L-803087	Somatostatin Receptor	Neurological Disease Cancer
L-803087 is a potent and selective *somatostatin sst4 receptor* agonist with a K_i of 0.7 nM. L-803087 is >280-fold higher than other somatostatin receptors. L-803087 facilitates AMPA-mediated hippocampal synaptic responses in vitro and increases kainate-induced seizures in mice .

HY-155193

XY-52	Others	Inflammation/Immunology
XY-52 (Compound 32) is a Stimulation-2 (ST2) inhibitor, with an IC₅₀ value of 5.68 μM in AlphaLISA assay, and 4.59 μM in HEK-Blue assay. XY-52 increases proinflammatory T-cell proliferation. XY-52 reduces the plasma sST2 and IFNγ biomarkers in the graft versus host disease (GVHD) mice model .

HY-P1139

Cortistatin-8 PCFWKTCK	GHSR	Metabolic Disease
Cortistatin-8 (CST-8; PCFWKTCK), a neuropeptide, is a GHS-R1a antagonist by counteracting the response of ghrelin on gastric acid secretion. Cortistatin-8 can modulate GH release from somatotroph cells. Cortistatin-8 is a synthetic CST-analogue devoid of any binding affinity to SST-R but capable to bind the GHS-R1a. Cortistatin-8 can exert antagonistic effects on ghrelin actions either in vitro or in vivo in animals .

HY-108501

(1R,1'S,3'R/1R,1'R,3'S)-L-054,264	Somatostatin Receptor	Neurological Disease
(1R,1'S,3'R/1R,1'R,3'S)-L-054,264 is a selective non-peptide human somatostatin receptor subtype 2 (sst₂) agonist. (1R,1'S,3'R/1R,1'R,3'S)-L-054,264 can be used in the study of retinal neuromodulation .

Cat. No.	Product Name	Target	Research Area

HY-P4917A

Somatostatin-14 (reduced) (TFA) SST 14 TFA	Peptides	Inflammation/Immunology
Somatostatin-14 (reduced) (SST 14) (TFA) is a peptide that can be discovered through peptide screening. Peptide screening is a research tool primarily used for identifying active peptides through immunoassays. It can be employed in protein interactions, functional analysis, antigen epitope screening, and is particularly useful in the research and development of active molecules .

HY-P1206

CH 275	Somatostatin Receptor	Neurological Disease
CH 275 is a peptide analog of somatostatin and binds preferably to somatostatin receptor 1 (sst₁) with a K_i of 52 nM . CH 275 acts as a potent and selective sst₁ agonist (IC₅₀=30.9 nM) and also displays IC₅₀ values of 345 nM, >1 μM, >10 μM, >10 μM for human sst₃, sst₄, sst₂ and sst₅, respectively . CH 275 can be used for the research of alzheimer’s disease .

HY-P1202

CYN 154806 1 Publications Verification	Somatostatin Receptor	Endocrinology
CYN 154806, a cyclic octapeptide, is a potent and selective *somatostatin sst2 receptor* antagonist, with pIC₅₀ values of 8.58, 5.41, 6.07, 5.76 and 6.48 for human recombinant sst2, sst1, sst3, sst4 and sst5 receptors respectively .

HY-P1202A

CYN 154806 TFA 1 Publications Verification	Somatostatin Receptor	Endocrinology
CYN 154806 TFA, a cyclic octapeptide, is a potent and selective somatostatin sst2 receptor antagonist, with pIC₅₀ values of 8.58, 5.41, 6.07, 5.76 and 6.48 for human recombinant sst2, sst1, sst3, sst4 and sst5 receptors respectively .

HY-P1932

Cortistatin-14	Somatostatin Receptor	Neurological Disease Inflammation/Immunology Endocrinology
Cortistatin-14 is a neuropeptide that shares structural similarities with somatostatin, working by binding to somatostatin receptors (sst1-sst5). Cortistatin-14 (TFA) has anticonvulsant, neuroprotective effects, and significant anti-inflammatory properties .

HY-P1932A

Cortistatin-14 TFA	Somatostatin Receptor	Neurological Disease Inflammation/Immunology Endocrinology
Cortistatin-14 (TFA), a neuropeptide have structural similarity to somatostatin-14, binds and exerts its function via the somatostatin receptors (sst1-sst5). Cortistatin-14 (TFA) shows anticonvulsive, neuroprotective effect and remarkable anti-inflammatory properties .

HY-P1203

BIM-23056	Somatostatin Receptor	Neurological Disease
BIM 23056, a linear octapeptide, is a potent *sst3* and *sst5* somatostatin receptor antagonist with K_i values of 10.8, 5.7, respectively .

HY-P4917

Somatostatin-14 (reduced) SST 14	Peptides	Others
Somatostatin-14 (reduced) (SST 14) is a polypeptide that can be found by peptide screening. Peptide screening is a research tool that pools active peptides primarily by immunoassay. Peptide screening can be used for protein interaction, functional analysis, epitope screening, especially in the field of agent research and development .

HY-P4469

PRL 3195	Somatostatin Receptor Urotensin Receptor	Cardiovascular Disease
PRL 3195 is a somatostatin receptor antagonist with K_is of 6, 17, 66, 1000 and 1000 nM for human somatostatin receptors (sst₅, sst₂, sst₃, sst₁ and sst₄, respectively) .

HY-P1203A

BIM-23056 TFA	Somatostatin Receptor	Neurological Disease
BIM 23056 TFA, a linear octapeptide, is a potent *sst3* and *sst5* somatostatin receptor antagonist with K_i values of 10.8, 5.7, respectively .

HY-P2090

Angiopeptin	Somatostatin Receptor Adenylate Cyclase	Cardiovascular Disease
Angiopeptin, a cyclic octapeptide analogue of somatostatin, is a weak *sst₂/sst₅* receptor partial agonist with IC₅₀ values of 0.26 nM and 6.92 nM, respectively. Angiopeptin is a potent inhibitor of growth hormone release and insulin-like growth factor-1 (IGF-1) production. Angiopeptin inhibits adenylate cyclase or stimulates extracellular acidification. Angiopeptin has the potential for coronary atherosclerosis research .

HY-P2090A

Angiopeptin TFA	Somatostatin Receptor Adenylate Cyclase	Cardiovascular Disease
Angiopeptin TFA, a cyclic octapeptide analogue of somatostatin, is a weak *sst₂/sst₅* receptor partial agonist with IC₅₀ values of 0.26 nM and 6.92 nM, respectively. Angiopeptin TFA is a potent inhibitor of growth hormone release and insulin-like growth factor-1 (IGF-1) production. Angiopeptin TFA inhibits adenylate cyclase or stimulates extracellular acidification. Angiopeptin TFA has the potential for coronary atherosclerosis research .

HY-111615A

J-2156 TFA	Somatostatin Receptor	Neurological Disease Inflammation/Immunology
J-2156 TFA is a high potent, selective *somatostatin receptor type 4 (SST₄* receptor) agonist with IC₅₀*s of 0.05 nM and 0.07 nM for human and rat SST₄* receptors, respectively. J-2156 TFA has anti-inflammatory activity and it is used for the relief of mechanical allodynia and mechanical hyperalgesia in the ipsilateral hindpaws in rats .

HY-16381

Pasireotide 5 Publications Verification SOM230	Somatostatin Receptor	Endocrinology Cancer
Pasireotide (SOM230), a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes *sst1/2/3/4/5, pK_i*=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide can suppress GH, IGF-I and ACTH secretion, indicating potential efficacy in acromegaly and Cushing's disease. Pasireotide also exhibits antisecretory, antiproliferative, and proapoptotic activity .

HY-16381A

Pasireotide acetate 5 Publications Verification SOM230 acetate	Somatostatin Receptor	Endocrinology Cancer
Pasireotide (SOM230) acetate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes *sst1/2/3/4/5, pK_i*=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide acetate can suppress GH, IGF-I and ACTH secretion, indicating potential efficacy in acromegaly and Cushing's disease. Pasireotide acetate also exhibits antisecretory, antiproliferative, and proapoptotic activity .

HY-P5085

Acetyl-Octreotide	Peptides	Others
Acetyl-octreotide is a reduced linear peptide. Acetyl-octreotide can synthesize Re(V)-cyclized peptides in aqueous methanol solutions with *low Sst* receptor binding affinities** .

HY-P3294

Onzigolide BIM-23A760; TBR-760	Dopamine Receptor Somatostatin Receptor	Neurological Disease Cancer
Onzigolide (BIM-23A760), a chimeric dopamine-somatostatin compound, shows potent agonist activity at both DA type 2 (D2R) and SST type 2 (SSTR2) receptors .

HY-P1201

Cyclosomatostatin	Somatostatin Receptor	Cancer
Cyclosomatostatin is a potent somatostatin (SST) receptor antagonist. Cyclosomatostatin can inhibit somatostatin receptor type 1 (SSTR1) signaling and decreases cell proliferation, ALDH+ cell population size and sphere-formation in colorectal cancer (CRC) cells .

HY-P1201A

Cyclosomatostatin TFA	Somatostatin Receptor	Cancer
Cyclosomatostatin TFA is a potent somatostatin (SST) receptor antagonist. Cyclosomatostatin TFA can inhibit somatostatin receptor type 1 (SSTR1) signaling and decreases cell proliferation, ALDH+ cell population size and sphere-formation in colorectal cancer (CRC) cells .

HY-P3958

BIM-23027	Peptides	Neurological Disease
BIM-23027 is a selective agonist of *sst₂* receptor (EC₅₀=0.32 nM), with similar effect to somatostatin (SRIF), a cyclic tetradecapeptide. BIM-23027 stimulates dopamine release, which is mediated by a Glu-dependent mechanism .

HY-P1139

Cortistatin-8 PCFWKTCK	GHSR	Metabolic Disease
Cortistatin-8 (CST-8; PCFWKTCK), a neuropeptide, is a GHS-R1a antagonist by counteracting the response of ghrelin on gastric acid secretion. Cortistatin-8 can modulate GH release from somatotroph cells. Cortistatin-8 is a synthetic CST-analogue devoid of any binding affinity to SST-R but capable to bind the GHS-R1a. Cortistatin-8 can exert antagonistic effects on ghrelin actions either in vitro or in vivo in animals .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: